Fig 1: Knockdown of MNK1 promoted the proliferation of BCa cells both in vitro and in vivo. (A) The efficacy of stable silence or over-expression of MNK1 in BCa cell lines were detected by Western blotting. GADPH was adopted as the loading control. (B) CCK-8 assay was carried out to investigate the proliferation ability of BCa cells that stably knocked down or up-regulated MNK1. (C) Xenograft assay showed that mice inoculated with MNK1-silenced cells exhibited tumors in bigger volume and heavier weight than those with MNK1-control cells. *, P<0.05; **, P<0.01. MNK1, MAP kinase-interacting kinase 1; BCa, bladder cancer.
Fig 2: MNK1 was down-regulated in BCa samples and cell lines. (A) The mRNA expression of MNK1 was apparently lower in recurrent BCa tissues than those in the para-carcinoma normal bladder epithelium or primary BCa specimens in GEO dataset (GSE13507). (B,C) qPCR and western blotting detected the mRNA and protein expression levels of MNK1 in 12 BCa tissues versus the adjacent normal tissues from our center. (D) The protein expression level of MNK1 in seven human BCa cell lines in comparison with the immortal bladder cell line SV-HUC-1. GAPDH was used as a loading control. **, P<0.01. MNK1, MAP kinase-interacting kinase 1; BCa, bladder cancer; qPCR, quantitative real-time PCR.
Fig 3: IHC staining assay showed that down-regulation of MNK1 was closely related to poor prognosis in BCa. (A) Representative images of MNK1 in normal bladder tissues and BCa specimens in strong, moderate or weak staining intensity. (B) Distribution of MNK1 staining intensity in these 129 BCa samples. (C,D) Low-MNK1 BCa patients had a shorter OS rate than those with high-MNK1 expression. (E) Kaplan-Meier subgroup survival analysis revealed that low MNK1 expression had a better discrimination in T1-2 and N- of BCa patients. MNK1, MAP kinase-interacting kinase 1; BCa, bladder cancer.
Supplier Page from Abcam for Anti-MNK1 (phospho T385) antibody [EPR2370]